Luis Báez-Díaz

2.6k total citations · 1 hit paper
20 papers, 1.4k citations indexed

About

Luis Báez-Díaz is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luis Báez-Díaz has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 8 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luis Báez-Díaz's work include Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (6 papers). Luis Báez-Díaz is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (6 papers). Luis Báez-Díaz collaborates with scholars based in United States, Canada and Puerto Rico. Luis Báez-Díaz's co-authors include Norman Wolmark, Linda H. Colangelo, Mark S. Roh, Morton S. Kahlenberg, Nicholas J. Petrelli, Greg Yothers, Melvin Deutsch, Michael J. O’Connell, Carmen J. Allegra and Louis Fehrenbacher and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Luis Báez-Díaz

20 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

2009 690 citations Mark S. Roh, Linda H. Colangelo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Luis Báez-Díaz

Since Specialization

Citations

This map shows the geographic impact of Luis Báez-Díaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Báez-Díaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Báez-Díaz more than expected).

Fields of papers citing papers by Luis Báez-Díaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Báez-Díaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Báez-Díaz. The network helps show where Luis Báez-Díaz may publish in the future.

Co-authorship network of co-authors of Luis Báez-Díaz

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Báez-Díaz. A scholar is included among the top collaborators of Luis Báez-Díaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Báez-Díaz. Luis Báez-Díaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41 2023 ·Breast Cancer Research and Treatment ·Priya Rastogi, Gong Tang, Saima Hassan, Charles E. Geyer, Catherine A. Azar, Gustav Magrinat, Jennifer M. Suga, Harry D. Bear, Luis Báez-Díaz, (unknown), Jean-François Boileau, Adam Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Greg Yothers, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	4
2	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology) 2022 ·Breast Cancer Research and Treatment ·Charles E. Geyer, Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher, Patrick J. Ward, Jonathan Polikoff, Adam Brufsky, Louise Provencher, Alexander Paterson, John Hamm, (unknown), Luis Báez-Díaz, Thomas B. Julian, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	4
3	Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer 2022 ·Breast Cancer Research and Treatment ·Patricia A. Ganz, Hanna Bandos, Charles E. Geyer, André Robidoux, Alexander Paterson, Jonathan Polikoff, Luis Báez-Díaz, Adam Brufsky, Louis Fehrenbacher, A Parsons, Patrick J. Ward, Louise Provencher, John Hamm, Philip J. Stella, (unknown), Richard G. Margolese, Henry R. Shibata, Edith A. Perez, Norman Wolmark	1
4	MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice 2021 ·JNCI Cancer Spectrum ·Alexander Paterson, Peter C. Lucas, Stewart Anderson, Eleftherios P. Mamounas, Adam Brufsky, Luis Báez-Díaz, Karen King, Thomas E. Lad, André Robidoux, (unknown), (unknown), Juan Carlos Tercero, (unknown), Antonio C. Wolff, Louis Fehrenbacher, Norman Wolmark, Roger R. Gomis	9
5	A randomized trial of nurse‐administered behavioral interventions to manage anticipatory nausea and vomiting in chemotherapy 2020 ·Cancer Medicine ·Jonathan Hunter, Robert Maunder, Dawen Sui, Mary Jane Esplen, Alejandro Chaoul, Michael Fisch, Roland L. Bassett, (unknown), (unknown), Lucas Wong, Luis Báez-Díaz, Lorenzo Cohen	18
6	Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population 2018 ·Journal of Clinical Oncology ·Jennifer J. Hu, James J. Urbanic, L. D. Case, Cristiane Takita, Jean L. Wright, Doris Brown, Carl D. Langefeld, Mark O. Lively, Sandra E. Mitchell, (unknown), David Bryant, Kathy Baglan, Jon Strasser, Luis Báez-Díaz, Glenn J. Lesser, Edward G. Shaw	38
7	Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590) 2017 ·Cancer ·Aarti Bhatia, Ju‐Whei Lee, Harlan A. Pinto, Charlotte Jacobs, Paul J. Limburg, Philip Rubin, Robert M. Arusell, Eamonn P. Dunphy, Janardan D. Khandekar, (unknown), Luis Báez-Díaz, Paul Celano, Shuli Li, Yi Li, Barbara Burtness, George L. Adams, Kishan J. Pandya	23
8	Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 2017 ·Cancer Research ·(unknown), (unknown), Priya Rastogi, CE Geyer, Louis Fehrenbacher, (unknown), Zoneddy Dayao, Rachel Rabinovitch, (unknown), P. Flynn, Luis Báez-Díaz, Soonmyung Paik, SM Swain, EP Mamounas, (unknown), Norman Wolmark	29
9	A patient with white blood cell counts more than a million: A diagnostic and therapeutic challenge. 2016 ·PubMed ·(unknown), (unknown), Luis Báez-Díaz, (unknown)	1
10	A Hispanic female patient with heartburn: A rare presentation of Paroxysmal Nocturnal Hemoglobinuria. 2016 ·PubMed ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Luis Báez-Díaz, (unknown)	1
11	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. 2016 ·Journal of Clinical Oncology ·André Robidoux, Gong Tang, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Luis Báez-Díaz, (unknown), Richard G. Margolese, William B. Farrar, Adam Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	18
12	Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer 2013 ·Obstetrical & Gynecological Survey ·Harry D. Bear, Gong Tang, Priya Rastogi, Charles E. Geyer, André Robidoux, James N. Atkins, Luis Báez-Díaz, Adam Brufsky, Rita S. Mehta, Louis Fehrenbacher, James A. Young, Francis M. Senecal, Rakesh Gaur, Richard G. Margolese, Paul T. Adams, Howard M. Gross, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, (unknown)	64
13	Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer 2012 ·New England Journal of Medicine ·Harry D. Bear, Gong Tang, Priya Rastogi, Charles E. Geyer, André Robidoux, James N. Atkins, Luis Báez-Díaz, Adam Brufsky, Rita S. Mehta, Louis Fehrenbacher, James A. Young, Francis M. Senecal, Rakesh Gaur, Richard G. Margolese, Paul T. Adams, Howard M. Gross, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	320
14	Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial 2012 ·The Lancet Oncology ·Alexander Paterson, Stewart Anderson, Barry C. Lembersky, Louis Fehrenbacher, Carla I. Falkson, Karen King, Lorna Weir, Adam Brufsky, Shaker R. Dakhil, Thomas E. Lad, Luis Báez-Díaz, Julie R. Gralow, André Robidoux, Edith A. Perez, Ping Zheng, Charles E. Geyer, Sandra M. Swain, Joseph P. Costantino, Eleftherios P. Mamounas, Norman Wolmark	128
15	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. 2012 ·Journal of Clinical Oncology ·André Robidoux, Gong Tang, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Luis Báez-Díaz, (unknown), Richard G. Margolese, William B. Farrar, Adam Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	38
16	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. 2012 ·Journal of Clinical Oncology ·André Robidoux, (unknown), Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Luis Báez-Díaz, (unknown), Richard G. Margolese, William B. Farrar, Adam Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	21
17	S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. 2011 ·Cancer Research ·(unknown), (unknown), BC Lembersky, Louis Fehrenbacher, CI Falkson, (unknown), (unknown), Adam Brufsky, Shaker R. Dakhil, Thomas E. Lad, Luis Báez-Díaz, JR Gralow, A. Robidoux, EA Perez, Ping Zheng, CE Geyer, SM Swain, J. P. Costantino, EP Mamounas, Norman Wolmark	14
18	PD07-08: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. 2011 ·Cancer Research ·(unknown), Gong Tang, Priya Rastogi, CE Geyer, André Rogatko, JN Atkins, Luis Báez-Díaz, Adam Brufsky, (unknown), Louis Fehrenbacher, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), J. P. Costantino, SM Swain, EP Mamounas, Norman Wolmark	6
19	Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03 breakdown → 2009 ·Journal of Clinical Oncology ·Mark S. Roh, Linda H. Colangelo, Michael J. O’Connell, Greg Yothers, Melvin Deutsch, Carmen J. Allegra, Morton S. Kahlenberg, Luis Báez-Díaz, (unknown), Nicholas J. Petrelli, Norman Wolmark	690
20	Evaluation of Breast Cancer Care under Puerto Rico's Health Care Reform 2007 ·Journal of Health Care for the Poor and Underserved ·Thomas N. Chirikos, (unknown), (unknown), (unknown), (unknown), Luis Báez-Díaz	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact